Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.
about
Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene familyCNS active O-linked glycopeptidesIntra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and MetastasisFunctional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cellsTransmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles.N-Glycosylation of the MUC1 mucin in epithelial cells and secretions.Tumour-associated carbohydrate antigens in breast cancer.Protein biomarkers in cancer: natural glycoprotein microarray approachesPolypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines.The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.Elevated Golgi pH in breast and colorectal cancer cells correlates with the expression of oncofetal carbohydrate T-antigen.Chemical in-gel deglycosylation of O-glycoproteins improves their staining and mass spectrometric identification.Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis.Trefoil factor family domains represent highly efficient conformational determinants for N-linked N,N'-di-N-acetyllactosediamine (LacdiNAc) synthesis.Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in MiceComplex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cellsChemical glycosylation in the synthesis of glycoconjugate antitumour vaccines.Systems-level modeling of cellular glycosylation reaction networks: O-linked glycan formation on natural selectin ligands.Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma.Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature.Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.Golgi pH, its regulation and roles in human disease.The sweet tooth of biopharmaceuticals: importance of recombinant protein glycosylation analysis.Localized Chemical Remodeling for Live Cell Imaging of Protein-Specific Glycoform.Novel O-linked glycans containing 6'-sulfo-Gal/GalNAc of MUC1 secreted from human breast cancer YMB-S cells: possible carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.MUC1 (CD227): a multi-tasked molecule.A Single Excitation-Duplexed Imaging Strategy for Profiling Cell Surface Protein-Specific Glycoforms.Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming mucins through the recombinant expression of their protein domains.Profiling surface glycans on live cells and tissues using quantum dot-lectin nanoconjugates.O-linked N,N'-diacetyllactosamine (LacdiNAc)-modified glycans in extracellular matrix glycoproteins are specifically phosphorylated at subterminal N-acetylglucosamine.Improved method for immunostaining of mucin separated by supported molecular matrix electrophoresis by optimizing the matrix composition and fixation procedure.Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes.Initiation of mammalian O-mannosylation in vivo is independent of a consensus sequence and controlled by peptide regions within and upstream of the alpha-dystroglycan mucin domain.Glucuronic acid can extend O-linked core 1 glycans, but it contributes only weakly to the negative surface charge of Drosophila melanogaster Schneider-2 cells.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity.Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cellsEvidence for core 2 to core 1 O-glycan remodeling during the recycling of MUC1.Human trefoil factor 2 is a lectin that binds α-GlcNAc-capped mucin glycans with antibiotic activity against Helicobacter pylori.
P2860
Q26864268-92B24FA0-0DD7-4D16-9450-3BAC4A5AEB2DQ27021529-3462ED93-F3F7-4FBD-B7D8-0D8691FE03B9Q28066445-39BA722B-C74E-4A9B-82DC-ADCDCB3AC349Q28269958-B75383D7-DAAC-4924-87D7-1E1DA2F70D04Q33217688-20D8302E-8B2E-4BE1-B2E3-60AEE15FD1B9Q33238547-7FDAB8DF-6837-4EA9-96C1-5C8E1CAF51A3Q34048052-9C4B21CE-174A-4B9E-AB58-91334473E78AQ34062987-849B1AAD-7E2C-4E49-B536-4EFE4CC47DCBQ34198013-81CD9F76-0782-45E2-B671-AA11B93CBB3DQ34471553-B4A37BCC-8428-46C1-AB3A-C329B9338907Q34503522-BFE8BD66-5419-4703-BE9A-87017EB133AEQ34666353-F24CEAB5-F7C1-4F1B-A21E-8AAA7292679DQ35069229-74129A02-E73D-424A-8A46-E8517500842AQ35247136-0F49E1A9-4FC7-4A76-80E3-DEC9FB1B1EDCQ35705462-EB75FFF0-C2CF-4C06-B78B-4F8C4C5F3F5AQ35953085-DA65C624-85DC-4D7E-AA4C-75B680A454D1Q36371928-7A684706-216F-4BD0-A416-5E8AF75FD3DEQ36802325-70D7204B-E056-4AF5-BF60-90BC2DF6D880Q37090734-B0DE7C20-6DD9-4DD1-B238-99A143EBE4B0Q37100578-EE34BE74-47CA-47C7-A508-9A9E8F7C1322Q37355949-728BF3CC-E53A-4CF2-BF6E-5BB813505952Q37512647-07D48F93-7977-49BB-BA9D-27184B5D65EEQ37876406-63B9D8E5-8234-43F0-9030-029D57160132Q38029304-8D14DB1A-63A8-4CF0-B935-F325E3310100Q38288036-13CB9828-0AB3-4731-9C8E-9B695168B68AQ38332313-50C747A8-BF15-438E-BFD2-64EDD24E5501Q38570769-52AE5EB2-981B-4CD6-8674-F077D6216257Q38784321-1CE1652C-2C24-4202-8964-2192AF2994D1Q39202871-9D23CC92-2F7D-4AE8-8CF5-94D9FEA4F5C1Q39316822-22C76A86-3E5C-410E-A386-37A5AABEAAF0Q39369642-70D5174E-3B05-4F7F-AE9A-4669C8229D82Q39516745-8AA1A184-0CCB-485F-A3F9-400A5DF20B1FQ39700918-EB647338-C961-488E-A243-F8CE74BADB29Q39985380-18E7CAAE-9191-4956-A1C4-CC8BDAE6381AQ39991378-1F1443C1-B01F-4A1C-9152-A6C356112A77Q40197046-3424FE9F-3323-454B-9569-4FB4976BC5FEQ40379188-0EFA1AF8-EC3E-4D0C-A579-7603C3D41BF7Q40638785-50E63756-7136-4906-9DC7-2C3EF4B9142EQ41506874-694F8769-1A6C-452D-99FE-81B470EB8BE9Q42926733-C9CAE280-FAF0-43B9-9E0B-D38F8A140DD1
P2860
Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@ast
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@en
type
label
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@ast
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@en
prefLabel
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@ast
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@en
P2860
P356
P1476
Recombinant MUC1 probe authent ...... nt core 2-based glycosylation.
@en
P2093
Franz-Georg Hanisch
Stefan Müller
P2860
P304
26103-26112
P356
10.1074/JBC.M202921200
P407
P577
2002-05-08T00:00:00Z